Abstract 728P
Background
Cervical function damage from fertility-sparing surgery reduces pregnancy success rate. Recently, immunotherapy has made significant advances in treating cervical cancer (CC). Herein, we conducted this study to evaluate the efficacy and safety of chemo + tislelizumab (TIS, a PD-L1 inhibitor) in young pts with CC who required fertility preservation.
Methods
In this trial, FIGO2018 stage IB1-IB3 or IIIC1r (localized cervical lesions) CC and having fertility needs were enrolled. Pts received 4 cycles chemo (175 mg/m2 paclitaxel + 70 mg/m2 cisplatin/AUC 5-6 carboplatin, Q3W) + TIS (200 mg, Q3W), followed by surgery-diagnostic cervical conization and sentinel lymph node (SLN) biopsy (IIIC1r stage with pelvic lymph node [PLN] systematic dissection)-upon achieving radiographic complete response (CR). After surgery, pts with pathological complete response (pCR) in all samples will undergo 2-cycle chemo + TIS, followed by TIS maintenance therapy (MT) for 1 year. If the first conization did not achieve pCR for localized cervical lesion only, a second conization was performed after 2-cycle chemo + TIS, followed by 1 year of TIS MT upon achieving pCR. Primary endpoint was pCR (SLN/PLNs + cervical conization) after surgery.
Results
Between Mar. 2022 and Apr. 2024, 8 pts (mean age 31 years) were enrolled, with 2 having stage IIIC1r disease. All 8 pts received chemo + TIS; of these, 6 pts completed 4 cycles, CR rate was 83.3%(5/6), and patients with CR received surgery. The pCR was 100% (5/5) in pts who underwent surgery, with 1 reaching a pCR after the second conization. Amenorrhea occurred in 3 of 5 pts, with 2 recovering normal menstruation post-chemo, and 1 had not returned after 3 weeks post-last chemo+TIS. During 4 cycles of chemo+TIS therapy (n=7), common TEAEs included rash (62.5%), neutropenia (62.5%), and leukopenia (62.5%), alanine aminotransferase increased (50.0%). At data cutoff (median follow-up, 9 months, range 2-25), 1 pt developed progression during MT, and 1 pt got pregnant 3 months post-MT.
Conclusions
Chemo + TIS could mediate tumor regression and eliminate micro-metastases with a tolerable safety profile, potentially preserving fertility in many pts previously considered ineligible.
Clinical trial identification
ChiCTR2300067495.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
733P - Efficacy and safety of sacituzumab govitecan (SG) in patients with advanced/metastatic endometrial cancer (EC): Updated results from TROPiCS-03
Presenter: Bradley Corr
Session: Poster session 01
734P - Impact of investigator-assessed response on overall survival (OS) in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG3031/RUBY trial
Presenter: Cara Mathews
Session: Poster session 01
735P - HRD signature (HRDsig) in endometrial cancer (EC)
Presenter: Bhavana Pothuri
Session: Poster session 01
736P - Exceptional clinical benefit (ECB) from immune checkpoint inhibitors (ICIs) in mismatch-repair deficient (MMRd) in recurrent /metastatic endometrial cancer (r/mEC): Are we curing a subset of MMRd EC patients (pts)?
Presenter: Juan Francisco Grau Béjar
Session: Poster session 01
737P - Characterization of tumor response with lenvatinib plus pembrolizumab (LEN + Pembro) in the ENGOT-en9/LEAP-001 study
Presenter: Anna Danska-Bidzinska
Session: Poster session 01
739P - Comparison of breast and gastric HER2 immunohistochemistry (IHC) scoring criteria in the assessment of endometrial endometrioid adenocarcinoma (EEA)
Presenter: Whitney Grither
Session: Poster session 01
740P - A monocentric analysis of ESCAT gene actionability detection in non-specific molecular profile (NSMP) early-stage endometrial cancer
Presenter: Luca Mastrantoni
Session: Poster session 01
741P - Comparison of the Idylla microsatellite instability (MSI) test with a gold standard MSI test and mismatch repair immunohistochemistry in endometrial cancer
Presenter: Ramona Erber
Session: Poster session 01
743P - Immunotherapy plus chemotherapy in the first-line treatment for primary advanced or recurrent endometrial cancer: An extracted individual patient data and trial-level meta-analysis
Presenter: Mariana Gouveia
Session: Poster session 01